Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 9/20 | 0.35 |
| ▸ | DRD4 | P21917 | 5/20 | 0.35 |
| ▸ | DRD3 | P35462 | 5/20 | 0.35 |
| ▸ | DRD1 | P21728 | 3/20 | 0.35 |
| ▸ | DRD5 | P21918 | 3/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.34 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.34 |
| ▸ | HTR5A | P47898 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | SRC | P12931 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5705543 | 0.91 | DRD2 (0.39) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL7787043 | 0.90 | DRD2 (0.38) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL7024588 | 0.84 | DRD2 (0.37) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL2985465 | 0.84 | DRD2 (0.34) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL2996951 | 0.83 | HDAC4 (0.44) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL4798227 | 0.82 | HDAC4 (0.44) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL7796579 | 0.82 | DRD2 (0.38) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL6256438 | 0.82 | DRD2 (0.38) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL6255238 | 0.80 | DRD2 (0.37) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL1420826 | 0.80 | HDAC4 (0.40) | HDAC4HDAC7HDAC5CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7459284-B2 | Chemiluminescent acridinium compounds and analogues thereof as substrates of hydrolytic enzymes | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-20060202179-A1 | Chemiluminescent Acridinium Compounds and Analogues thereof as Substrates of Hydrolytic Enzymes | BAYER CORPORATION (US) | 2006-09-14 | — | — | US | disclosed |
| US-7097995-B2 | Chemiluminescent acridinium compounds and analogues thereof as substrates of hydrolytic enzymes | BAYER CORP. (US) | 2006-08-29 | — | — | US | disclosed |
| US-20050032147-A1 | Chemiluminescent acridinum compounds and analogues thereof as substrates of hydrolytic enzymes | BAYER CORPORATION | 2005-02-10 | — | — | US | disclosed |
| US-6783948-B1 | USED IN DIAGNOSTIC IMMUNOASSAYS; HAS DISTINCTLY DIFFERENT LIGHT EMISSION CHARACTERISTICS (EMISSION WAVELENGTH, KINETICS, OR QUANTUM YIELD) | BAYER CORPORATION | 2004-08-31 | — | — | US | disclosed |
| EP-1203091-A1 | CHEMILUMINESCENT SUBSTRATES OF HYDROLYTIC ENZYMES SUCH AS PHOSPHATASES | Bayer Corporation (US) | 2002-05-08 | — | — | EP | disclosed |
| WO-2001009372-A1 | CHEMILUMINESCENT SUBSTRATES OF HYDROLYTIC ENZYMES SUCH AS PHOSPHATASES | BAYER CORPORATION (US) | 2001-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032147-A1 | Chemiluminescent acridinum compounds and analogues thereof as substrates of hydrolytic enzymes | MPO, LPO, PGLS | DRD2 3217/4885DRD4 3047/4885DRD3 3264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.